TABLE 2.
Multivariate analysis of factors associated with the progression of patients with severe COVID‐19
| Variable | Univariate Logistic analysis | Multivariate Logistic analysis | ||
|---|---|---|---|---|
| OR (95%CI) | P‐value | OR (95%CI) | P‐value | |
| Male | 1.080 (0.605‐1.928) | .795 | ||
| Age ≥ 65 y | 4.402 (2.201‐8.806) | .000 | 2.767 (1.180‐6.491) | .019 |
| Underlying chronic diseases | 2.410 (1.274‐4.558) | .007 | 3.584 (1.545‐8.316) | .003 |
| Leukocytosis | 1.024 (0.420‐3.250) | .520 | ||
| Leukocytopenia | 0.652 (0.320‐1.526) | .652 | ||
| Lymphocytopenia | 2.526 (0.754‐6.586) | .426 | ||
| Haemoglobin > 175 g/L | 0.452 (0.003‐1.960) | .446 | ||
| Platelets < 300 × 109/L | 0.652 (0.320‐1.526) | .652 | ||
| Cr > 104 μmol/L | 3.706 (2.411‐5.030) | .035 | 4.206 (2.336‐9.872) | .001 |
| Troponin > 26.2 pg/mL | 6.006 (2.611‐8.952) | .001 | 8.220 (1.360‐9.007) | .001 |
| Alanine aminotransferase > 100 U/L | 2.206 (2.336‐6.872) | .023 | 1.552 (0.760‐4.269) | .214 |
| Lactate dehydrogenase > 245 U/L | 5.220 (1.324‐10.826) | .000 | 11.032 (0.814‐8.466) | .869 |
| CRP > 10 mg/L | 21.003 (0.498‐36.142) | .856 | ||
| PCT > 0.05 ng/mL | 23.014 (5.620‐46.008) | .000 | 12.410 (4.433‐34.744) | .000 |
| ESR > 20 mm/h | 0.652 (0.320‐1.526) | .536 | ||
| PT > 12.5 s | 1.528 (0.960‐6.339) | .426 | ||
| D‐dimer > 500 ng/mL | 1.208 (0.526‐4.006) | .284 | ||
| IL‐6 > 7pg/mL | 3.263 (1.526‐6.002) | .000 | 4.001 (1.630‐6.339) | .000 |
| Use of methylprednisolone | 0.059 (0.020‐0.171) | .000 | 0.054 (0.017‐0.173) | .000 |
| Use of Oseltamivir | 0.851 (0.476‐1.520) | .851 | ||
| Use of Arbidol Hydrochloride | 2.396 (0.521‐11.017) | .262 | ||
| Use of Lopinavir/Ritonavir or Darunavirand/Cobicistat | 0.943 (0.530‐1.679) | .843 | ||